Piccart M
Institut Jules Bordet, Department of Chemotherapy, Brussels, Belgium.
Anticancer Drugs. 1996 Aug;7 Suppl 2:5-7.
Metastatic breast cancer is a major and increasing public health problem. The 5-year survival for this disease is only 15%, and while hormonal and chemotherapeutic options have had a significant impact on long-term survival for patients with localized disease, treatment for disseminated disease remains essentially palliative. New treatment options are urgently needed to improve the prospects for patients with metastatic breast cancer, particularly for those with disease characteristics indicating a particularly poor prognosis. Docetaxel (Taxotere) is a promising new drug and has shown encouraging activity in patients with disease resistant to anthracyclines and in patients with visceral metastases, both of which indicate a poor prognosis. Although docetaxel is, at present, only licensed for use in patients with anthracycline-resistant disease, this highly active drug should now be developed for first-line treatment, and eventually for adjuvant use.
转移性乳腺癌是一个日益严重的重大公共卫生问题。这种疾病的5年生存率仅为15%，虽然激素治疗和化疗方案对局限性疾病患者的长期生存产生了重大影响，但播散性疾病的治疗基本上仍为姑息性治疗。迫切需要新的治疗方案来改善转移性乳腺癌患者的前景，特别是对于那些具有预后特别差的疾病特征的患者。多西他赛（泰索帝）是一种有前景的新药，在对蒽环类药物耐药的患者以及内脏转移患者中显示出令人鼓舞的活性，这两类患者均提示预后不良。虽然多西他赛目前仅被批准用于蒽环类药物耐药的患者，但这种高活性药物现在应开发用于一线治疗，并最终用于辅助治疗。
